BiOptix Announces Expansion of Sales and Marketing Efforts into Europe.
BOULDER, Colo. and BASEL, Switzerland, Sept. 24, 2012 /PRNewswire/ -- BiOptix officially announced that it has expanded sales and marketing efforts outside of the United States and into Europe with participation in MipTec, The Leading European Event for Drug Discovery. MipTec is being held at Congress Center Basel, in Basel, Switzerland from September 24 – 27, 2012.
"MipTec is the ideal venue to launch our European Sales and Marketing efforts," noted Ken Wilczek, Vice President of Sales and Marketing for BiOptix. Held in conjunction with BioValley Life Sciences Week 2012, MipTec and Basel are in the middle of the European "biotech triangle" that connects the industry in Germany, France and Switzerland. "Participation in MipTec places BiOptix in the center of the European Biotech and Pharmaceutical industries—exactly where we need to be to promote BiOptix Enhanced Surface Plasmon Resonance technology to a global audience of elite scientific leaders," continued Wilczek.
In a continued effort to expand European presence and message, BiOptix will also participate and support additional scientific symposia in Europe this fall. BiOptix is also supporting The Label-Free Technologies meeting in Amsterdam, and the PEGS Europe Symposia, to be held in Vienna. Both events will be in November, 2012 and will highlight the BiOptix 404pi.
Surface Plasmon Resonance is an advanced and highly sensitive optical technology that can measure refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.
BiOptix Diagnostics Corporation, a privately held firm based in Boulder, Colorado has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at: www.bioptix.com